Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) News
Filter JAZZ News Items
JAZZ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JAZZ News Highlights
- JAZZ's 30 day story count now stands at 8.
- Over the past 25 days, the trend for JAZZ's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- CBD, DRUG and NOVA are the most mentioned tickers in articles about JAZZ.
Latest JAZZ News From Around the Web
Below are the latest news stories about JAZZ PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate JAZZ as an investment opportunity.
Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
The 3 Best Growth Stocks to Buy in the Biotech SectorThese three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. |
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart HealthJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients th |
My Top Cannabis Stock to Buy in 2023 and Hold For 10 YearsA few years ago, the cannabis industry attracted much interest from investors following significant regulatory changes in Canada and anticipated progress elsewhere in developed countries. Let's first review how Jazz Pharmaceuticals entered the cannabis market. In May 2021, the company acquired GW Pharmaceuticals, a drugmaker focusing on developing cannabidiol (CBD)-based medicines. |
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical PipelineJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca® (lurbinectedin), zanidatamab and JZP898. |
Jazz Pharmaceuticals Secures Eight Additional Provincial Reimbursements for Vyxeos® for Treatment of Adults with Newly Diagnosed Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related ChangesJazz Pharmaceuticals plc (NASDAQ: JAZZ) announced today that Vyxeos® (daunorubicin and cytarabine liposome for injection) is now included on eight additional provincial drug formularies, including British Columbia, Ontario, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Alberta, and Newfoundland and Labrador. Vyxeos is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia (AML) with myelodysplasia-related changes |
Those who invested in Jazz Pharmaceuticals (NASDAQ:JAZZ) three years ago are up 29%Buying a low-cost index fund will get you the average market return. But in any diversified portfolio of stocks, you'll... |
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2022 Earnings Call TranscriptJazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good day, and welcome to the Jazz Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there’ll be a question-and-answer session. Instructions will be given at that time. […] |
Jazz Pharmaceuticals (JAZZ) Reports Q4 Loss, Misses Revenue EstimatesJazz (JAZZ) delivered earnings and revenue surprises of -113.73% and 0.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial GuidanceJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2022 and provided financial guidance for 2023. |